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ARTICLE
Balancing mcr-1 expression and bacterial survival is
a delicate equilibrium between essential cellular
defence mechanisms
Qiue Yang1, Mei Li1, Owen B. Spiller1, Diego O. Andrey 1,2, Philip Hinchliffe3, Hui Li4, Craig MacLean 5,
Pannika Niumsup6, Lydia Powell7, Manon Pritchard7, Andrei Papkou5, Yingbo Shen8, Edward Portal1,
Kirsty Sands1, James Spencer3, Uttapoln Tansawai6, David Thomas7, Shaolin Wang8, Yang Wang8,
Jianzhong Shen8 & Timothy Walsh1
MCR-1 is a lipid A modifying enzyme that confers resistance to the antibiotic colistin. Here,
we analyse the impact of MCR-1 expression on E. coli morphology, ﬁtness, competitiveness,
immune stimulation and virulence. Increased expression of mcr-1 results in decreased growth
rate, cell viability, competitive ability and signiﬁcant degradation in cell membrane and
cytoplasmic structures, compared to expression of catalytically inactive MCR-1 (E246A) or
MCR-1 soluble component. Lipopolysaccharide (LPS) extracted from mcr-1 strains induces
lower production of IL-6 and TNF, when compared to control LPS. Compared to their parent
strains, high-level colistin resistance mutants (HLCRMs) show reduced ﬁtness (relative ﬁt-
ness is 0.41–0.78) and highly attenuated virulence in a Galleria mellonella infection model.
Furthermore, HLCRMs are more susceptible to most antibiotics than their respective parent
strains. Our results show that the bacterium is challenged to ﬁnd a delicate equilibrium
between expression of MCR-1-mediated colistin resistance and minimalizing toxicity and thus
ensuring cell survival.
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The global concern over colistin resistance has profoundimplications as to how we successfully manage and treatserious Gram-negative infections, particularly those caused
by Enterobacteriaceae1,2. Until recently, our understanding of
colistin resistance was limited to chromosomal changes such as the
pmrA/pmrB activation of arnBCADTEF and pmrE, that collectively
modiﬁes lipopolysaccharide (LPS), the component of the Gram-
negative outer membrane by the addition of 4-amino-4-deoxy-L-
arabinose3. However, the advent and subsequent reporting of
plasmid-mediated colistin resistance, mcr-1, in both animal and
human health, has invoked commentaries announcing a return to
the pre-antibiotic era. Since our lab described mcr-1 in November
2015, it has been reported in over 40 countries. Regrettably, as the
main bacterial host of mcr-1 is Escherichia coli, there are also
signiﬁcant public health4 and environmental issues as MCR-1-
positive E. coli (MCRPEC) has been reported from migratory
birds4,5, ﬂies4, dogs4, imported reptiles6, rivers7 and inevitably
public water facilities8. The widespread reporting ofmcr-1 since the
ﬁrst sequence was published is unprecedented above any previous
resistance mechanism9,10. This is, in part, also due to increased
surveillance; nonetheless, its rapid global dissemination only fur-
ther increases the critical need for better global biosafety contain-
ment and novel drug development.
The clinical impact of mcr-1 is still unknown. Of the few
clinical studies reporting MCRPEC from infections, most lack
assessment of risk factors to determine whether MCRPEC have a
different pathogenic proﬁle to non-MCRPEC11–14. In China
where MCRPEC is disseminated throughout the Chinese food
industry and environment, it has been shown to colonise healthy
volunteers and patients15. Whether the expression of mcr-1 gene
modulates pathogenicity in E. coli remains to be explored.
Those few studies that have examined the association of
MCRPEC with virulent factors and pathogenicity have shown
little or no difference16. However, these studies involved only a
few isolates and applied different methods, so a direct correlation
remains unclear. Notwithstanding, mcr-1 plasmids have been
reported in variety of different MLST clades only some of which
fall into the B2 group of human pathogens10,16. Most noticeable,
is that mcr-1 is now starting to emerge in ST131, a virulent strain
associated with a variety of clinical infections10,17. However,
mcr-1 encodes an enzyme that catalyses the transfer of phos-
phoethanolamine onto a phosphate of the N-acetylglucosamine
head group of lipid A in the bacterial outer membrane (Fig. 1)
18,19, which may modify the structure of lipid A and alter its
ability to induce the innate immune response and modify the
clinical pathogenicity of bacterial infections. Furthermore, colistin
MICs displayed by MCRPEC are moderate (usually 2–8 mg l−1)
when compared to the level of colistin resistance (usually
8–256 mg l−1) mediated by, for example, increased expression of
pmrA/pmrB, inferring that the expression of mcr-1 is tightly
controlled3,9,10,16. This, in part, is supported by recent studies on
plasmid copy number where mcr-1 were only found on plasmids
of a relatively low copy number20,21.
Here, we investigate the impact of mcr-1 expression on E. coli
survival, ﬁtness and virulence. Furthermore, we analyse the via-
bility, virulence and high-level colistin resistance stability of
MCRPEC high-level colistin-resistant mutants.
Results
Generic background and plasmid copy number. The wild-type
MCRPEC isolates (PN16, PN21, PN23, PN24, PN25, PN42 and
PN43) chosen for this study were selected from a collection from
Phitsanulok, Thailand (Supplementary Table 1) and in keeping
with the known epidemiology of MCRPEC4. Isolates were chosen
from a variety of sources: chicken meat (PN16), chicken faeces
(PN21), duck faeces (PN23, PN24 and PN25) and human faeces
(PN42 and PN43) (Supplementary Table 1). Isolates PN16 and
PN21, possessed mcr-1 plasmids with an Incl2 backbone and
PN23, PN24, PN25 and PN42 possessed IncX4 mcr-1 plasmids.
Unusually, mcr-1 was carried on the chromosome of isolate PN43
(Supplementary Fig. 1). The genomes of the strains were
sequenced and varied considerably in the number and variety of
antibiotic resistance genes. For example, apart from mcr-1, PN23
possessed one additional gene, tetB, where as PN42 carried
numerous antibiotic resistance genes (Supplementary Table 1).
The genetic maps showing the immediate context of mcr-1 in the
wild-type isolates are shown in Supplementary Fig. 2. The MLSTs
for each MCRPEC were grouped as follows: ST2040 (PN16), new
variant of ST24 (PN21), ST1211 (PN23), ST3631 (PN24), ST101
(PN25), ST744 (PN42) and ST410 (PN43), conﬁrming that the
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Fig. 1Molecular model of colistin binding to lipid A. a Schematic of phosphoethanolamine transfer to the 1-PO4 group of hexa-acylated lipid A as catalysed
by MCR-1. b Models of colistin (blue sticks) binding to lipid A (left) or phosphoethanolamine-lipid A (right) (spheres coloured green, red, blue and orange
for C, O, N and P atoms, respectively). The model is based on the NMR and docking studies of polymixin B binding to lipid A with lipid A coordinates from
PDB 3fxi22 and colistin coordinates adapted from the NMR structure of polymixin B bound to lipid A23. The positively charged Dab colistin residues closely
interact with the negatively-charged 1′ and 4′ phosphate groups of lipid A, reducing the net-negative charge of lipid A. The hydrophobic leucine residues
and tail of colistin A interact with the fatty acid tails of lipid A, allowing colistin A to insert into, and disrupt, the bacterial outer membrane. b (right), model
of colistin binding to phosphoethanolamine-lipid A indicates addition of positively charged phosphoethanolamine onto the 1′-PO4 of lipid A likely interferes
with the interaction of positively charged Dab8 and Dab9 side chains with the phosphate group, preventing colistin binding to the outer membrane of
Gram-negative bacteria. Figure created using Pymol (https://www.pymol.org/)
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MCRPEC isolates used in this study are not clonal (Supplemen-
tary Table 1). MRCPEC possessing some of these MLST groups
have been reported previously10,16. The copy number of mcr-1
was assessed by qPCR (quantitative PCR) using 16S ribosomal
RNA as a standard reference copy number. All isolates possessed
mcr-1 at a copy number ranging between 1 (chromosomal copy of
isolate PN43) and 5.6 in keeping with other recent studies20,21
(Supplementary Table 1).
Effects of mcr-1 overexpression on bacterial growth and ﬁtness.
The mcr-1 coding region obtained from pHNSHP45 was con-
structed into plasmid pBAD to generate strain E. coli TOP10 mcr-
1/pBAD (mcr-1/pBAD) (Supplementary Table 2, see Methods).
To determine whether mcr-1 affects bacterial growth rate and
ﬁtness, we examined growth curves, quantitative real-time PCR
(qRT-PCR) and competition assays for E. coli TOP10 carrying the
mcr-1-pBAD plasmid construct. The expression level of mcr-1
was induced by increasing concentrations of L-arabinose and
measured by qRT-PCR (Fig. 2b). Maximal mcr-1 induction was
observed at 0.02% L-arabinose, where mcr-1 expression was
approximately twofold and threefold more than the arabinose
concentrations of 0.002% and 0.2%, respectively. As shown in
Fig. 2a, after 8 h, the growth rates of E. coli strains induced by
0.2% and 0.02% (w/v) of L-arabinose showed approximately a 3-
log10 unit decrease when compared to E.coli TOP10 (mcr-1/
pBAD) without L-arabinose. As the initial inoculum was ~7.5
log10 (c.f.u. per ml), and this decreased to ~5 log10, it also suggests
overexpression of mcr-1 decreases cell populations. In vitro
competition experiments were also performed to determine the
effect of mcr-1 expression on the relative ﬁtness of E. coli (mcr-1/
pBAD) with different mcr-1 levels (Methods). Results are shown
in Fig. 2c and indicate that increased mcr-1 expression levels were
associated with a signiﬁcant ﬁtness burden in vitro. For example,
inducing high levels of mcr-1 expression with 0.2% L-arabinose
remarkably decreases relative ﬁtness (average relative ﬁtness 0.43,
p = 0.0022, using non-parametric Mann–Whitney test) by >50%
relative to uninduced controls (Fig. 2c and Supplementary
Table 6). To eliminate these observations being singularly due to
the overexpression of a random protein, our negative control,
blaTEM-1b, when overexpressed showed very similar growth curves
to the uninduced E. coli cells (Supplementary Fig. 4C).
Overexpression of mcr-1 affects cellular morphology. As mcr-1
encodes the transfer of phosphoethanolamine onto a phosphate of
the N-acetylglucosamine head group of lipid A in the bacterial
outer membrane9. We employed transmission electron microscopy
(TEM) and study the cellular morphology of E. coli (TOP10) under
induced (0.2% (w/v) L-arabinose) and non-induced conditions
(Fig. 3). Both control strains, E. coli TOP10 with pBADminusmcr-
1, and E. coli TOP10 (mcr-1/pBAD) without L-arabinose induction,
showed normal cellular characteristics with a multi-layered cell
surface consisting of a distinct, structured outer membrane, a
peptidoglycan layer in the periplasmic space, a normal cytoplasmic
membrane and typically granular cytoplasm (Fig. 3a and Fig. 3b).
Signiﬁcant morphological changes were however, observed in E.
coli TOP10 (mcr-1/pBAD) treated with 0.2% L-arabinose for 8 h
(Fig. 3c). In particular, with the outer cell membrane cell envelope
(Fig. 3f). The outer membrane region exhibited altered structural
integrity, varying markedly in thickness and density, and it could
not be differentiated from the cell wall or the cytoplasmic mem-
brane (Fig. 3d–f). TEM analysis on E. coli where mcr-1 is over-
expressed shows other gross cellular changes including complete
loss of the ‘bacilli’ morphology and absence of electron-dense
material appeared as empty ‘ghost’ cells (Fig. 3c). By comparison,
E. coli TOP10 with pBAD minus mcr-1, and E. coli TOP10 (mcr-1/
pBAD) without L-arabinose induction possess homogeneous elec-
tron densities in the cytoplasm and exhibited unaltered multi-
layers of cell membrane (Fig. 3a, b) conﬁrming that it is the high-
level expression of mcr-1 that has induced these gross morpholo-
gical changes. In order to rule out effects caused by high con-
centration of L-arabinose, we examined E. coli TOP10 with pBAD
alone (minus mcr-1) with 0.2% L-arabinose induction (Supple-
mentary Fig. 3). Induction resulted in an intact cell wall with a
well-deﬁned inner and outer membrane, and a highly homo-
geneous electron density in cytoplasm were observed (Supple-
mentary Fig. 3), further supporting that cell membrane
impairment is due to the expression of mcr-1 gene only.
Effects of mcr-1 overexpression on bacterial survival. As the
growth curves from Fig. 2a suggest that overexpression of mcr-1
reduces cell counts, and given its profound effect on the E. coli
cell structure and morphology, we investigated the effects of mcr-
1 on cellular viability and bioﬁlm assembly, using LIVE/DEAD®
staining with confocal laser scanning microscopy (CLSM) ima-
ging and COMSTAT analysis in E. coli TOP10 (mcr-1/pBAD)
bioﬁlms with/without 0.2% L-arabinose induction (Fig. 4). The
observed marked reduction of viability in bacterial cell over-
expressing mcr-1 (Fig. 4), was contrast with the minimal reduc-
tion in bacterial viability observed in E. coli TOP10 with pBAD
minus mcr-1, and E. coli TOP10 (mcr-1/pBAD minus L-arabinose
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Fig. 2 Effects of mcr-1 overexpression on bacterial growth and ﬁtness in vitro. a Overproducing mcr-1 causes variable effects on growth rate depending on
the concentrations of L-arabinose (n= 3). b The expression levels of mcr-1 gene induced by increasing concentrations of arabinose were measured by qRT-
PCR (n= 2). c Relative ﬁtness of mcr-1 overexpressing strain mcr-1/pBAD competing control strain pHT315 under increasing concentrations of L-arabinose
(0.0002% vs 0%, 0.002% vs 0%, 0.02% vs 0%, 0.2% vs 0%). Error bars represent the SD (n= 6). The differences in ﬁtness were tested using non-
parametric Mann–Whitney test, ** indicates the p values is <0.05. The average relative ﬁtness and p values are listed in Supplementary Table 6
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induction) (Fig. 4a, b). COMSTAT analysis of the CLSM bioﬁlm
images revealed that relative dead/live biomass ratio (Fig. 4d) of
induced E. coli TOP10 (mcr-1/pBAD) was at least six times higher
than E. coli TOP10 with pBAD minus mcr-1, and E. coli TOP10
(mcr-1/pBAD) minus arabinose (0.33 vs 0.06; p< 0.001, using
one-way analysis of variance (ANOVA)). Morphological
alterations were also apparent in CLSM imaging, where the live
cells (green) in Fig. 3c appeared more spherical and ‘bloated’, in
keeping with the changes observed in the TEM studies (Fig. 3c).
Overexpression of blaTEM-1b showed no evidence of increased cell
death compared to that of E. coli TOP10 with pBAD minus mcr-
1, and E. coli TOP10 (mcr-1/pBAD minus L-arabinose induction
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Fig. 3 TEM micrographs of untreated and treated E.coli. In a and b, TEM micrographs of untreated control cells (E. coli TOP10 with pBAD minus mcr-1, and E.
coli TOP10 (mcr-1/pBAD) without L-arabinose induction, respectively); both cells are intact with a well-deﬁned inner and outer membrane, and showed a
highly homogeneous electron density in cytoplasm region (d and e). c TEM micrographs of mcr-1 overproducing cells; the damaging outer membrane and
some completely lysed cells were observed (f)
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Fig. 4 The toxic effects of mcr-1 overexpression on cell viability. a–c Confocal laser scanning microscopy images of cells treated with/without L-arabinose
and stained with LIVE/DEAD® (n= 3). Live and dead cells presented green and red colour, respectively. Scale bar is 15 µm. d Ratio of dead to live bacteria
(biomass) obtained from CLSM z-stack images through COMSTAT analysis of E. coli bioﬁlms grown for 16 h in LB broth, followed by ±L-arabinose (0.2%
w/v; 8 h) treatment, where the bioﬁlms were stained with LIVE/DEAD® (n= 4). The COMSTAT data was assessed using one-way analysis of variance
(ANOVA) followed by Tukey–Kramer multiple comparisons post hoc test. Statistical signiﬁcance was set at p< 0.05
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(Fig. 5c)) providing further evidence that the cellular effects seen
with increased expression of MCR-1 are not due to the ﬁtness
burden of protein expression.
mcr-1-mediated membrane-bound resistance mechanism. Our
previous study has shown that MCR-1 is a membrane-bound
enzyme consisting of ﬁve hydrophobic transmembrane helixes
and a soluble form located in the periplasmic domain9. To
examine whether the transmembrane domain or MCR-1 catalytic
domain (typiﬁed by aspartate at position 246) plays a role on cell
integrity and bacterial ﬁtness, MCR-1 (E246A), and a MCR-1
soluble domain (residues 219–541 and lacking the N-terminal
membrane-bound region) mutant, were cloned into a pBAD-hisA
plasmid. Both constructed plasmids were transferred into TOP10
cells and induced with 0.2% (w/v) L-arabinose at exponential
phase. Results show that increased expression of MCR-1 (E246A)
produced a toxic effect on the E. coli cells as evidenced by
decreased growth rate (Supplementary Fig. 4), signiﬁcant mem-
brane degradation (Supplementary Fig. 5) and moderate ﬁtness
loss (Fig. 6a). In contrast, the increased expression of the MCR-1
soluble domain (219–451) did not show any marked changes in
growth rate, ﬁtness loss or membrane architecture (Fig. 5b, f,
Fig. 6a, and Supplementary Figs. 4 and 5). However, the toxic
effects of the MCR-1 (E246A) mutant is moderate, compared to
the marked effect of MCR-1 wild-type (Figs. 2–4). For example,
increased expression of the full-length mcr-1 gene caused at least
three times higher bacterial death than overproducing incomplete
MCR-1 (E246A) (dead/live bacteria ratio, 0.33 vs 0.09) (Fig. 5a, f).
Therefore, our data indicate that the ﬁtness loss and the
destruction of the membrane architecture is due to both the
embedding of the protein in the E. coli outer membrane and the
phosphoethanolamine modiﬁcation of LPS. Phosphoethanola-
mine addition on lipid A in MCRPEC has been observed by ESI-
QTOF/MS (Supplementary Fig. 6), compared to that of non-
MCRPEC.
mcr-1-mediated LPS modiﬁcation reduced the stimulation of
macrophage. mcr-1 encodes an enzyme that catalyses the transfer
of phosphoethanolamine onto a phosphate of the N-acet-
ylglucosamine head group of lipid A, and its expression affects
cell morphology (Fig. 3) and survival (Fig. 4). Therefore, to
investigate whether the modiﬁed LPS of MCRPEC alters the
activation of human macrophage THP-1, LPS-mediated human
macrophage stimulation assays were undertaken. The macro-
phages were activated by serial concentrations (4.5, 0.45, 0.045
and 0.0045 ng per ml) of LPS extracted from E. coli TOP10 with
pBAD minus mcr-1, and E. coli TOP10 (mcr-1/pBAD plus 0.2%
L-arabinose). The production of interleukin (IL)-6 and tumour
necrosis factor (TNF) were assayed by using DuoSet® ELISA kit
(R&D systems, UK). The concentrations of IL-6 produced by
macrophages induced by unmodiﬁed LPS were consistently
higher than IL-6 levels produced by MCR-1 modiﬁed LPS at 8
and 24 h (Fig. 7a, b). Additionally, TNF-alpha levels were also
higher in macrophages stimulated by unmodiﬁed LPS than
compared to modiﬁed LPS (Fig. 7c).
Acquisition and stability of high-level colistin resistance
mutants. MCRPEC was ﬁrst discovered on the premise that E.
coli can rarely acquire colistin resistance by chromosomal
mutations alone and that the levels mediated by mcr-1 are
moderate compared with other mechanisms1,2,9. Data
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Fig. 5 The toxic effects of mcr-1 mutants on cell viability. a–c Confocal laser scanning microscopy images of cells treated with L-arabinose (0.2% w/v; 8 h)
and stained with LIVE/DEAD® (n= 4). Live and dead cells presented in green and red colour, respectively. d and e Confocal laser scanning microscopy
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previously published by us would suggest that the level of in vivo
colistin resistance mediated by MCRPEC can protect the cells
compared to control strains9. However, the data from Figs. 2–4
would suggest that the expression of mcr-1 is also very tightly
controlled because of the ﬁtness cost of increased mcr-1
expression. We explored whether MCRPEC could generate
high-level colistin resistance mutants (HLCRMs) over non-
MCRPECs and investigated how damaging these changes would
be. HLCRMs were generated from the seven wild-type MCRPEC
strains described in Supplementary Table 1. These isolates
possessed low-level resistance to colistin (4–8 mg l−1), and
HLCRMs were generated through exposure to increasing con-
centrations of colistin. After a 14-day serial colistin challenge, all
seven wild-type MCRPEC strains exhibited an increase in
colistin resistance with a four to 64-fold increase in colistin
MICs (Supplementary Fig. 7A and Supplementary Table 4). The
rate of increase and ﬁnal level of resistance varied considerably,
with PN16 and PN23 reaching 256 mg l−1; PN21, PN25 and
PN43 reaching 128 mg l−1; PN42 reaching 32 mg l−1, yet PN24
could be increased to 16 mg l−1.
We also exposed E. coli TOP10 (mcr-1/pBAD), E. coli TOP10
(pBAD) and E. coli TOP10 to the same level of passaging
(Supplementary Fig. 7B and Supplementary Table 5). E. coli
TOP10 (mcr-1/pBAD) (in the absence of arabinose) displayed a
64-fold (from 0.5 to 32mg l−1) increase in colistin MICs. However,
both E. coli TOP10 (pBAD) and E. coli TOP10 did not show any
elevation in colistin MICs remaining at 0.125mg l−1 ±1 dilution over
the 14-day challenge. These data indicate that the increase in colistin
resistance shown by E. coli TOP10 (mcr-1/pBAD) is singularly due
to the presence of mcr-1. Both the expression level and copy number
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of mcr-1 gene were determined by qRT-PCR for all MCRPEC
isolates (Supplementary Fig. 8 and Supplementary Table 1).
Compared with the wild-type strains, no signiﬁcant difference in
plasmid copy number andmcr-1 expression could be observed in the
corresponding HLCRMs except for MRCPECs isolates PN21 and
PN25, where the expression of mcr-1 has increased by ~11-fold and
threefold, respectively (Supplementary Fig. 8).
Given the ﬁtness cost of mcr-1 to E. coli and the fact that the
HLCRMs are likely to mediate higher resistance in vivo and be
more problematic to treat, the stability of these HLCRMs needed
to be assessed for their high-level colistin resistance stability.
Accordingly, the 14-day challenged HLCRMs were subsequently
serially passaged in colistin-free medium to determine if the high-
level colistin-resistance phenotype could be reversed. Three
MCRPECs, PN24, PN25 and PN42, showed the same level of
colistin resistance as their respective HLCRMs (day-14 mutants),
after 14-day passages in lysogeny broth (LB) broth without
colistin indicating that the high-level of colistin resistance was
very stable (Supplementary Fig. 7C). However, MCRPECs PN16,
PN21, PN23 and PN43 showed a marked decreased in colistin
resistance during passaging in antibiotic-free medium with
HLCRM PN43 being the most unstable (highest loss of colistin
resistant population) followed by HLCRM derived from isolates
PN23, PN16 and PN21 (Supplementary Fig. 7C).
In vitro relative ﬁtness of HLCRMs. Our data examining the
physiological burden of mcr-1 would suggest that the HLCRMs
might even be defective in ﬁtness and pathogenicity. Therefore, to
compare the growth rates of the wild-type MCRPEC isolates with
their respective HLCRMs, we measured growth over a serial time
course of HLCRMs strains that showed different resistance levels of
resistance to colistin at day 0, 3, 7, 11 and 14. Most of the HLCRMs
grew up to threefold slower than their wild-type parent isolates
and, in particular, those mutants recovered at day 11 and day 14
(Supplementary Fig. 9A–G). The exception being PN16 where
there was no signiﬁcant difference in growth rate between the
parent and its corresponding HLCRM (even day-14 mutant)
(Supplementary Fig. 9A). Additionally, we also examined the
growth curves of HLCRMs generated from E. coli TOP10 (mcr-1/
pBAD). Similarly, day-8 and day-14 mutants (both MICs of 16 and
32mg l−1 for colistin, respectively) showed a decreased growth
compared to that of their parental strains (Supplementary Fig. 9H).
Based on our data from bacterial growth curves, we propose
there is substantial ﬁtness disadvantage to the HLCRMs when
compared to their MCRPEC parent strains. To test this
hypothesis, in vitro competition assays were performed and
HLCRMs were directly competed against their MCRPEC parental
strains. The ﬁtness of the MRCPEC parent strains and HLCRMs
were relative to the growth of the control strain that was ﬁxed at
1.0 (Methods) (Fig. 6b). Most (6/7) of the day-14 HLCRMs had
lower competitive ﬁtness than that of their corresponding parent
strains (Fig. 6b) with HLCRMs derived from PN21, PN23, PN24,
PN25 and PN42 possessing a relative ﬁtness of 0.4–0.6 and
HLCRM PN43 and relative ﬁtness rate of 0.78 (Mann–Whitney
test-corrected p = 0.0022) (Fig. 8a and Supplementary Table 6).
The PN21 and PN23 mutants, the former has 11-fold increased
mcr-1 gene expression (Supplementary Fig. 8), were associated
with the highest ﬁtness burden (~0.41, p = 0.0022) (Fig. 6b and
Supplementary Table 6). The exception was HLCRM derived
from PN16 that had a ﬁtness rate similar to its parent strain
(~0.94, p = 0.1320) (Fig. 6b and Supplementary Table 6). We also
examined the ﬁtness cost for E. coli TOP10 (mcr-1/pBAD), E. coli
TOP10 (pBAD) and E. coli TOP10 (Fig. 6c). Day 3 and 4
HLCRMs of E. coli TOP10 (mcr-1/pBAD) had slightly less ﬁtness
(1.0 vs 1.1 of E. coli TOP10 (pBAD) and E. coli TOP10) and day 8
and 14 were less ﬁt (0.83 vs 1.1, and 0.79 vs 1.1, respectively)
(Fig. 6c). Generally, our data show a signiﬁcant ﬁtness burden
with HLCRMs compared to their MCRPEC parent strains.
Virulence reduction of MCRPEC and HLCRMs. To determine
whether the level of virulence of HLCRMs have been reduced
compared to the MCRPEC parental strains, we used Galleria
mellonella as a model of infection24,25. Larvae were infected with
each of the MCRPEC parental strains and their respective
HLCRMs, with differing bacterium inoculums in order to illicit
appropriate live and dead larvae populations. The mortality of
larvae was dependent on the number of bacteria injected (data
not shown) and this was varied to show the greatest effect with
each parent/mutant pair. As shown in Fig. 6d and Supplementary
Fig. 10, a signiﬁcant decrease in G. mellonella killing was observed
in all HLCRMs, compared to their respective wild-type parent
strains. In particular, HLCRMs derived from MCRPECs PN16,
PN21 and PN23 gave mortality fractions of 0.33 (p = 0.0056,
Student’s t test), 0.13 (p = 0.0029) and 0.02 (p = 0.0003), respec-
tively, compared to their respective parent strains that were
between 0.8 and 1.0. Because the MCRPEC parental strains are
highly heterogeneous with respect to their genomic background,
the infection of G. mellonella resulted in different larvae survival
rates (Supplementary Fig. 10). However, when we compared the
morphological changes using TEM analysis, there was no sig-
niﬁcant change between mutants and their corresponding
MRCPEC parents (Fig. 8b, c), even there was a decrease in G.
mellonella killing (p = 0.0029) exhibited in PN21 (Fig. 8a).
In wild-type strains, the level of colistin resistance mediated by
mcr-1 gene is often moderate (2–8 mg l−1). The in vitro generated
HLCRMs possessed reduced ﬁtness and virulence. We also
determined that even the low level of colistin resistance mediated
by mcr-1 gene in clinical strains attenuates bacterial virulence in
G. mellonella killing model
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Fig. 8 G. mellonella killing data and TEM micrographs of strain PN21. a G.mellonella mortality rate in PN21 parental strain (D0) and its mutant (D14). Error
bars represent the SD (n= 3) and p value was calculated by Student’s t test (t= 6.509, d.f= 4). b and c indicated TEM micrographs of parental strain PN21
(D0) and PN21(D14) mutant, respectively. Membranes for both strains are intact with a highly homogeneous electron density in cytoplasm region
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02149-0 ARTICLE
NATURE COMMUNICATIONS |8:  2054 |DOI: 10.1038/s41467-017-02149-0 |www.nature.com/naturecommunications 7
the G. mellonella infection model. We chose four non-MCRPEC
clinical strains, belonging to different ST types: ST638 (ff112),
ST589 (ff141), ST127 (ff156) and ST648 (CX37), which is one of
diverse ST groups associated with mcr-1 gene in China10. Three
different mcr-1 plasmids isolated from MCRPEC strains (PN16,
PN23 and ZJ487) were transferred to these non-MCRPEC strains
by electroporation. We have shown that the acquisition of mcr-1
naturally occurring plasmids do not affect bacterial growth of the
host (wild-type clinical strains) strain and so their ﬁtness cost is
modest (Supplementary Fig. 11). However, their virulence is
markedly depleted (Fig. 9) supporting our hypothesis that the loss
of virulence shown by MCRPEC is not due to growth rate but by
the activity of mcr-1 on the E. coli outer membrane (Fig. 3).
Sequencing analysis of mcr-1 genetic contexts. To elucidate
genetic changes during the evolution of high levels of colistin
resistance, whole-genomic sequencing was performed on all seven
wild-type parental strains (day 0) and their isogenic HLCRMs
(day 14). For each strain, a read coverage of at least 80-fold was
generated and trimmed using Trim Galore and the genomes were
de novo-assembled into contigs using SPAdes (3.9.0) with pre-
deﬁned kmers set (Methods). When comparing genomes with
their parental strains, the seven HLCRMs showed no amino acid
mutations in mcr-1-carring contigs including their promoter and
the immediate surrounding genetic contexts. In addition, they all
possess mcr-1-carrying plasmids, exception of strain PN43, which
mcr-1 gene located in chromosome (Supplementary Table 1 and
Supplementary Fig. 5). As shown in Supplementary Fig. 1A, there
are three representative genetic contexts ofmcr-1-carrying contigs
were identiﬁed in seven MCRPEC. Firstly, the mcr-1 identiﬁed on
chromosome in PN43 isolate was ﬂanked directly by ISapl1, the
genetic context of which is identical to other chromosomal mcr-1
gene (accession number: KY421935, LT594504 and
ENQ00000000), except that a ﬂanking hypothetical open-reading
frame is truncated by IS1294. Of note, in two IncI2 plasmids from
PN16 and PN21 isolates, the genetic context ofmcr-1 are identical
to pHNSHP45 (accession number: KP347127) harbouring
IncI2 scaffold and type VI secretion system components (Sup-
plementary Fig. 1B). The rest of four mcr-1 positive IncX4 plas-
mids from PN23, PN24, PN25 and PN42 isolates exhibit
remarkable similarity to the backbone of pMCR-NJ-IncX4
(accession number: KX447768) (Supplementary Fig. 1C).
Discussion
Acquiring antibiotic resistance by mutation or horizontal gene
transfer tends to be associated with a ﬁtness cost26–28. This cost
plays a key in limiting the spread and maintenance of resistance
in pathogen populations by generating selection against resistant
strains under conditions where antibiotic doses are low, for
example, during transmission between hosts28,29. However,
recent studies have challenged this paradigm and provide evi-
dence supporting the notion that, at least in some systems, the
evolution of resistance can be associated with ﬁtness advantages
including the enhanced ability to cause disease30,31,32. We have
shown that the case for mcr-1 imposing a ﬁtness cost on its E. coli
host is substantial and increased expression of mcr-1 not only
impairs cell growth (Fig. 2a) and diminishes bacterial ﬁtness
(Fig. 2c), but also alters the cell’s architecture (Fig. 3c) and kills
the bacteria (Fig. 4c). Evolving colistin resistance by acquiring
mcr-1 therefore challenges bacterial populations with an evolu-
tionary trade-off: high-level expression of mcr-1 provide protec-
tion against the antibiotic, but this increase in resistance
compromises growth rate, ﬁtness, membrane structural integrity
and increases cellular death. This trade-off may explain several
important phenomena. First, mcr-1-mediated colistin MICs are at
best moderate (usually 2–8 mg l−1) when compared to colistin
resistance (8–256 mg l−1) mediated by pmrA/pmrB3,9,10,16. Sec-
ondly, we show that mcr-1 plasmid copy number is very low
when compared to other plasmid-mediated mechanisms, eg,
IncA/C plasmids carrying blaNDM-1 and this appears to protect
the cell from too many copies of mcr-121,33.
As a negative control, we show that the high expression of
blaTEM-1 has little, if any, effect on E. coli ﬁtness and survival
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Fig. 9 Kaplan–Meier plots showing the percent survival of G. mellonella over 72 h post infection with MCRPEC and non-MCRPEC human clinical strains.
Survival curves were plotted using the Kaplan–Meier method (GraphPad Software). Error bars represent the SD (n= 3) and p value for a (t= 8.654, d.f=
4), b (t= 8.050, d.f= 4), c (t= 12.07, d.f= 4 for strain ff112 with pMCR-1(PN16) and t= 3.479, d.f= 4 for strain ff112 with pMCR-1(PN23)) and d (t=
3.801, d.f= 4) were calculated by Student’s t test
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(Fig. 5c, Supplementary Figs. 3C and 4C), and therefore the
effects witnessed with MCR-1 are due to its incorporation into
the E. coli membrane or by its catalytic action—the phos-
phoethanolamine modiﬁcation of LPS. It is interesting to note
that only a few mobile membrane-associated antibiotic resistance
mechanisms have been characterised. One of them is the tetra-
cycline efﬂux system, eg, tetA(B), which is tightly regulated by its
neighbouring gene, tetR. It has been shown that overproduction
of tetA is lethal, which is probably due to its effect on the
membrane topology34–36. Unlike the tetA-like efﬂux pump sys-
tem, mcr-1 does not possess an adjacent repressor to control its
expression and its expression is controlled by other regulatory
systems such as low plasmid copy number. Compared with the
considerable burden of high expression of MCR-1 (Figs. 2–4), the
toxic effects of its two derivatives, MCR-1 E246A and MCR-1
soluble region, are moderate, which can be observed by some
restoration of its outer membrane integrity and a reduction in
death rate (Fig. 5, Supplementary Figs. 3 and 4). However, as the
toxic effects are more evident in MCR-1 E246A than the MCR-1
soluble region, MCR-1’s cellular burden is due to both the
embedding of the protein in the E. coli outer membrane and
MCR-1’s phosphoethanolamine modiﬁcation of LPS.
China has now withdrawn colistin as an animal growth pro-
moter and is now being deployed in human medicine4,37. How-
ever, the notion that MCRPEC will drastically diminish on
withdrawal of colistin is parsimonious and naive. Our data pre-
viously, and the stability data on HLCRMs herein, suggests that
colistin resistance in MCRPEC and HLCRMs can be stable9.
Additionally, our data on E. coli TOP10 (mcr-1/pBAD) shows
that HLCRMs can be generated from a lab-strain, but only after
acquisition of mcr-1suggesting the increase in colistin resistance is
not dependent on the strain background that is further supported
by the fact that all our selected wild-type MRCPECs readily
generated HLCRMs. Finally, it is possible that colistin-resistant
strains will evolve compensatory adaptations that allow for mcr-1
to be expressed at high levels at a low ﬁtness cost. Compensatory
adaptation is routinely detected in vitro28, and there is some
evidence that compensatory adaptation maintains otherwise
costly resistance mutations in vivo38.
Due to its central clinical role in causing Gram-negative bac-
terial sepsis, lipid A as an immune modulator has been thor-
oughly scrutinised39,40. However, despite the fact that the
mechanisms of 4-amino-4-deoxy-L-arabinose and phosphoetha-
nolamine LPS modiﬁcation are well known, there have been very
few systematic studies examining their impact on lipid A as an
immune stimulant. Studies on Salmonella have examined the
addition of phosphoethanolamine and found no signiﬁcant
change in virulence41. These data are supported by a recent study
in Haemophilus ducreyi that used knockout deletions of phos-
phoethanolamine modifying genes (lptA, ptdA and ptdB) and
concluded that the triple mutant was a virulent as the parent42. A
recent study by John et al.43 examined the phosphoethanolamine
and its effect in Neisseria meningitidis by comparing invasive and
carrier isolates and found more phosphoethanolamine and sialic
acid substitutions from invasive strains suggesting that
phosphoethanolamine-lipid A modiﬁcation enhances virulence.
This ﬁnding also has been identiﬁed in non-mcr-1 mediated
colistin resistance in K. pneumoniae, where lipid A remodelling
mediated by the mgrB mutation, resulted in increased colistin
resistance enhancing the virulence of K. pneumoniae by
decreasing the afﬁnity of colistin and attenuating host defence
response44. These data are further supported by O’Brien and
colleagues examining Campylobacter jejuni phosphoethanola-
mine modiﬁed lipid A, showed increased recognition of a human
Toll-like receptor and increased commensal colonisation in
mice45. However, Zughaier et al.46 examined N. gonorrhoeae
phosphoethanolamine modiﬁed lipid A and showed that it
reduced autophagy in human macrophages and useful mechan-
ism to evade the host immune system. Thus far, there are no
similar studies on E. coli and this is the ﬁrst examining the effect
of mcr-1 on E. coli ﬁtness and virulence. The data presented in
this study indicate that E. coli (in this case, E. coli TOP10 (mcr-1/
pBAD)) is forced to ﬁnely tune the expression of mcr-1 or else the
overexpression becomes toxic resulting in profound changes in
the architecture of the outer membrane (Fig. 3c), causing leakage
of cellular cytoplasm (Fig. 3c) and death (Fig. 4c). Interestingly, in
a HLCRM (PN21) where that was at least 11-fold expression on
mcr-1 (Supplementary Fig. 8), we observed no cellular dete-
rioration (Fig. 9b, c), suggesting that PN21 may have a different
genetic makeup and is able to produce compensatory muta-
tions47. When we have examined the immediate mcr-1 genetic
context comparing HLCRMs and their respective wild-type par-
ents, no changes in the promoter regions in any of our seven
isogenic pairs could be identiﬁed (Supplementary Fig. 1). When
compared to their respective wild-type parental strains, most of
HLCRMs, except strains PN25 and PN42, showed no amino acid
mutations in PmrE, PmrAB, PmrC, PhoPQ, MgrB, ArnB/D,
CptA, EptB, IpxM, MicA and ArcAB, which are known to be
associated with colistin resistance3,48. However, in strains PN25
and PN42, amino acid mutations have been identiﬁed in PmrA
(R81S)48 and PmrB (V161M)49, respectively, which are respon-
sible for reducing susceptibility of colistin. Another ﬁnding is that
HLCRMs altered the susceptibility to other antimicrobials (Sup-
plementary Table 7). HLCRMs have obtained higher MICs of
colistin (16–256 mg l−1) by multiple passages in the increasing
concentrations of colistin. Conversely, these mutants are more
susceptible to other antibiotics (Supplementary Table 7), for
instance, expect strain PN24, the other six HLCMRs strains
caused one to 16-fold MIC reduction of chloramphenicol, com-
pared with their respective parental strains. The MICs of tige-
cycline, regarded as one of the last resorts to treat infections
caused by multidrug resistance bacteria, have one to 32-fold
reduced in all HLCRMs. This is likely due to mcr-1-mediated
membrane permeability in these strains.
As mcr-1 continues to spread globally, and the clinical impact
is assessed, it will be interesting to examine how virulent
MCRPEC compare with non-MCRPEC. In this study, mcr-1
positive plasmids were transferred to non-MCRPEC clinical
strains (ST638 (ff112), ST589 (ff141), ST127 (ff156) and ST648
(CX37)) by electroporation. We have shown that the growth rate
of all mcr-1-positive transformants appears to be lower than that
of their non-MCR parents, but the difference is not statistically
signiﬁcant (Supplementary Fig. 11). Compared to non-MCRPEC
strains from phylogenetic group D (considered as second-most
virulent ExPEC group), the mortality of G. mellonella showed a
marked reduction after acquisition of a mcr-1-positive plasmid
(Fig. 8). To conclude, it would appear the acquisition of mcr-1 by
E. coli is a ‘poisoned chalice’—on the one hand mcr-1 is required
to provide protection in a colistin-rich environment, yet acqui-
sition compromises the bacterium’s normal physiology; further-
more, overexpression results in acute ‘toxicity’.
Methods
Bacterial strains and growth conditions. Seven E. coli isolates carrying the mcr-1
gene (MCRPEC) were isolated and characterised from Thailand and used as par-
ental strains (Supplementary Table 1). Bacteria were grown in LB broth or chro-
mogenic agar (Lioﬁlchem, Roseto, Italy), supplemented with appropriate
antibiotics at 37 °C. E. coli TOP10 (mcr-1/pBAD) was constructed by cloning the
mcr-1 gene in-frame into low-copy number pBAD-hisA expression vector (Ther-
moFisher, UK) such that the expression of mcr-1 is controlled by the pBAD
promoter of the araBAD (arabinaose) operon that can be regulated with L-arabi-
nose induction50. Four non-MCRPEC clinical strains belonging to E. coli group D,
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were chosen as recipients for transformation by electroporation. All strains and
plasmids used in this study are listed in Supplementary Table 2.
Plasmid constructs. An MCR-1 non-active enzyme was created by a single sub-
stitution (E246A). Its encoding gene was excised from mcr-1-pUC19 (E246A)19
and sub-cloned into plasmid pBAD-HisA to generate E246A/pBAD. To test the
effect of the MCR-1 soluble domain on bacterial growth, the gene encoding the
MCR1 soluble domain (lacking the ﬁve predicted transmembrane helices; codons
219–541) was cloned into pBAD-HisA vector with forward and reverse primers
(mcr-1F soluble and mcr-1R soluble, Supplementary Table 3). As a negative con-
trol, a ß-lactamase gene, blaTEM-1b, a 861 bp fragment were generated by PCR with
forward and reverse primers (Supplementary Table 3) and then inserted into
pBAD-HisA vector using the restriction sites EcoRI and KpnI. All resultant plas-
mids were transformed into E. coli TOP10 cell (Invitrogen, UK), puriﬁed and its
integrity conﬁrmed by PCR, double restriction digestion and DNA sequencing.
Electroporation. Overnight cultures were diluted (1:50) in 5 ml fresh LB broth and
incubated at 37 °C (220 r.p.m.) until the cultures reached an OD600 value of 0.5–0.7.
Bacterial cell cultures were kept on ice for 20 min, followed by centrifugation at
5000 r.p.m. (14,000×g), 4 °C for 15 min. The pellets were then resuspended in 1 ml
chilled 10% glycerol and re-centrifuged for 15 min at 4 °C. After another two
washes in chilled 10% glycerol, supernatants were discarded and the pellets were
suspended in the residual glycerol. Subsequently, 50–100 ng of plasmid DNA were
added into 50 µl of electrocompetent cells and then the DNA cell mixture was
transferred into a chilled cuvette. EC3 (3.0 kv, 5.5 ms) programme was used for
electroporation (Bio-Rad MicroPulser, France). Immediately, 950 µl of warm LB
broth was added to the cuvette and thoroughly mixed, followed by incubation at 37
°C for 1 h, shaking vigorously at 220 r.p.m. A total of 100 μl aliquot were plated
onto a pre-warmed selective plate and incubated overnight at 37 °C.
Quantitative real-time PCR. Expression of mcr-1 was assayed by a two-step qRT-
PCR using primers mcr-1-qF, mcr-1-qR and mcr-1 probe, with Precision 2× qPCR
Mastermix (PrimerDesign, UK) following manufacturers’ protocol. Total RNA was
extracted from bacteria using the RNeasy Plus kit with on column DNase digestion
(Qiagen, Germany), followed by complementary DNA synthesis with DNA-
integrated genomic DNA (gDNA) removal using QuantiTect Reverse Transcrip-
tion kit (Qiagen, Germany), according to manufacturers’ protocol. The absence of
carry-over gDNA was veriﬁed for every experiment by comparative qPCR (or
standard PCR) in the absence of reverse transcriptase. rpoB expression level was
used as internal control using primers rpoB-qF, rpoB-qR and rpoB probe. Relative
expression results were obtained by the ΔΔCT analysis method using mean CT
value. For details of used primers and probes, see Supplementary Table 3.
For qPCR determination of mcr-1 copy numbers per cell, 0.1 ng of total gDNA
was used as template with primers mcr-1 qF, mcr-1 qR and mcr-1 probe and 16S
primers and probe (Supplementary Table 3). In parallel standard curves for mcr-1,
16S were obtained using as template serial dilutions of mcr-1-carring plasmid DNA
extracted from pSU18-mcr-1 strain19 (4.3 pg of DNA corresponding to 106 copies,
calculated through the website: http://cels.uri.edu/gsc/cndna.html) and E. coli
TOP10 (Invitrogen) total gDNA (5 ng corresponding to 106 cells)21, respectively.
Selection of induced high-level colistin-resistant mutants. HLCRMs were
generated from seven wild-type mcr-1 positive strains through 14-day serial pas-
saging with increasing concentrations of colistin (Alfa Aesar, US). Overnight cul-
tures of parent strains were diluted to 105 c.f.u. per ml and challenged with
different concentrations of colistin (from 0.125 to 256 mg l−1) for 18–20 h at 37 °C.
The next day, cultures in the last well that yielded visible bacterial growth were
mixed with the ﬁrst clear well (normally registered as the MIC) and challenged
with colistin as described above. Cultures at 3, 7, 11 and 14 days were retained and
stored at −80 °C for further analysis.
Stability of high-level colistin resistance in HLCRMs. To detect whether the
colistin resistance in HLCRMs is stable, ie, reversible or not, serial passages of
HLCRMs were performed in colistin-free medium. Overnight cultures of HLCRMs
were diluted (1:500) into fresh LB broth without colistin and incubated with vig-
orous shaking (220 r.p.m.) for 18 h. To measure the proportion of colistin resistance
bacterial population during reversion, overnight cultures were serial diluted, then
inoculated on two types of chromogenic agar: one type is free of antibiotics, the
other is containing various concentrations (8, 16, 32, 64, 128, 256mg l−1) of colistin
depending on the level of colistin resistance mediated by the HLCRM. The c.f.u. per
ml of colistin resistance cells were counted after 18–22 h incubation at 37 °C.
Confocal laser scanning microscopy imaging using LIVE/DEAD staining. E.
coli TOP10 (mcr-1/pBAD), E. coli TOP10 (pBAD only) and E. coli TOP10 (n = 4)
were grown overnight in LB broth supplemented with 100 mg l−1 ampicillin
(Fisher Chemical, UK) at 37 °C (120 r.p.m.). Overnight cultures were standardised
to OD6000.05 and inoculated (1:10; v/v) into 96-well glass-bottomed plates
(Whatman®, UK) in LB broth for 16 h (37 °C; 30 r.p.m.). The supernatant was
gently removed and the bioﬁlms were further incubated in fresh LB broth± L-
arabinose (0.2%, w/v) for 8 h. The supernatant was removed and the bioﬁlms
stained with 6% LIVE/DEAD® (v/v; BacLightTM Bacterial Viability Kit, Invitrogen)
in phosphate buffered saline (PBS) prior to CLSM imaging (Leica TCS SP5) with
ax63 lens. The CLSM z-stack images were analysed using COMSTAT image
analysis software for quantiﬁcation of bioﬁlm biomass51. The COMSTAT data was
assessed using one-way ANOVA followed by Tukey–Kramer Multiple comparisons
post hoc test. Statistical signiﬁcance was set at p < 0.05.
In vitro competition assays. In vitro competition experiments were used to
measure the relative ﬁtness of the mcr-1 HLCRMs, E. coli TOP10 (mcr-1/pBAD)
and E. coli TOP10 (pBAD only) and E. coli TOP10. These strains were competed
against a GFP-labelled E. coli DH5-alpha carrying plasmid pHT315-pAphA3′-gfp
for constitutive expression52 and ﬂow cytometry was used to measure changes in
the cell titre of the two strains during competition. All competitions were carried
out in M9 medium (Sigma-Aldrich, UK) with six replicates per strain/condition, as
previously described with some modiﬁcations53. For E. coli TOP10 (mcr-1/pBAD),
mcr-1 expression was induced in a controlled way by adding different concentra-
tions of L-arabinose (0, 0.0002, 0.002, 0.02 and 0.2%, w/v).
The bacteria were cultured overnight in LB supplemented with the appropriate
antibiotics (2 mg l−1 of colistin for HLCRMs, or 100 mg l−1 of ampicillin (Fisher
Chemical) for E. coli TOP10 (mcr-1/pBAD), E. coli TOP10 (pBAD) and the GFP-
labelled E. coli DH5-alpha. The overnight cultures were diluted 1:400 in M9 broth
and mixed at 1:1 ratio with GFP-labelled cells. Before starting the competitions, the
exact initial proportion of ﬂuorescent/non-ﬂuorescent cells was estimated using
ﬂow cytometry (for details see below). If the actual ratio was close to 1:1, we started
the competition by shifting the mixtures to a shaking incubator (37 °C, 225 r.p.m.).
Otherwise, the preparation procedure was repeated.
After 22 h (6 h for HLCRMs), the competed bacteria were diluted 1:400 in M9
and analysed on a ﬂow cytometer to estimate the resulting proportion of labelled vs
unlabelled cells. Flow cytometry was performed on an Accuri C6 (Becton Dickenson,
Biosciences, UK). The cell densities were adjusted to give ~1000 events per
microlitre. During data acquisition, a lower cut off was set at 10,000 for FSC-H and at
8000 for SSC-H. For each competition, we ensured that the GFP-labelled strain can
be well separated from non-ﬂuorescent strains by comparing non-mixed controls
(overlap is usually <2% of the cells). Relative ﬁtness was calculated using formula:
Relative fitness ¼
log2
p1
p0=ndilution
 
log2
1p1
ð1p0Þ=ndilution
  ;
where p0 is an initial proportion of an unlabelled stain, and p1 is a ﬁnal proportion of
an unlabelled stain after competition. The ndilution is the factor, which reﬂects a fold
difference in cell density at the beginning and at the end of the competition. For
HLCRMs, we expressed the ﬁtness of daughter strains relative to their parental
strains (ie, fdaughter/fparental) and followed the procedure of error propagation to
account for the uncertainty of the two estimates:
SE ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
SDdaughter
f daughter
 !2
þ SDparental
f parental
 !2vuut ;
where f and SD are a mean estimate and its SD for each corresponding strain based
on six replicates. Similarly, the relative ﬁtness of the HLCRMs at different L-arabinose
concentrations was represented as the relative ﬁtness at no induction (no L-
arabinose). The differences in ﬁtness were tested using non-parametric
Mann–Whitney test, and the p values were adjusted by Bonferroni method.
LPS isolation and macrophage stimulation. LPS was extracted using LPS
extraction kit (iNtRON Biotechnology, UK), according to the manufacturers’
instructions. To eliminate protein contamination, treatment with protease K was
performed prior to the extraction steps. The protease K (AppliChem, Germany)
(20 mg/ml) was added to the cell mixture and incubated at 56 °C for 1 h. The
efﬁciency of the LPS preparation was determined by Limulus Amebocyte Lysate
(LAL chromogenic Endotoxin Quantitation kit, ThermoFisher) to measure the LPS
concentration, according to the manufacturers’ instructions.
THP-1 human cells (American Type Culture Collection, ATCC TIB-202™)
were cultured with the medium (RPMI-1640 medium supplemented with 10 %
foetal calf serum, HEPES, L-glutamine, ampicillin and streptomycin) (Sigma-
Aldrich) in a humidiﬁed cell culture incubator with 5% CO2 at 37 °C. THP-1 cells
were differentiated into macrophage cells by stimulation with phorbol myristate
acetate (PMA). Cells were centrifuged and resuspended in fresh supplemented
RPMI-1604 medium to a concentration of 8 × 105 cells per ml. Phorbol myristate
acetate (10 ng ml−1) was added to diluted cells, and then aliquoted into 24-well
plate by adding 1 ml of cell suspension per well. The differentiation of THP-1
monocytes were complete after 48 h of incubation, as exempliﬁed by induction of
adherent cells phenotype under the microscope.
Phorbol myristate acetate and any non-adherent cells were removed by
replacement of the medium with fresh medium prior to addition of serial
concentrations of LPS (4.5, 0.45, 0.045, 0.0045, 0.00045 ng/ml) to the appropriate
wells in triplicate. Differentiated THP-1 cell cultures without LPS served as the
negative controls. The wells are thoroughly mixed and incubated at 37 °C for 24 h.
The samples were collected at 4, 6, 8 and 24 h and stored at −20 °C. The production
of macrophage-derived cytokines (IL-6 and TNF-alpha) were analysed using
DuoSet® ELISA kit (R&D systems), and cytokine concentrations were calculated
according to the manufacturers’ instructions.
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Morphological analysis by TEM. Overnight cultures were diluted into 50 ml of
fresh media supplemented with 100 mg l−1 ampicillin for mcr-1/pBAD and 2
mg l−1 colistin for PN21 strains, respectively. For mcr-1/pBAD strain, 0.2% of
L-arabinose was added to induce the overexpression of mcr-1. After 8 h incubation,
samples were ﬁxed by addition of glutaraldehyde to the broth to a ﬁnal con-
centration of 1%. Bacteria were harvested by collection onto 0.45 mm pore ﬁlters,
gently scraped off and dispersed in 4% low melting point agarose at 50 °C. Pre-
parations were allowed to gel at room temperature and cut into 1 mm cubes. Cubes
were post-ﬁxed for 2 h in 2% uranyl acetate, washed for 3 × 20 min in reverse
osmosis puriﬁed water and dehydrated through graded propan-2-ol (50%, 70%,
90% for 10 min each, 100% for 2 × 15 min), inﬁltrated with LR white acrylic resin
(London Resin Company, Aldermaston, UK) (50% in propan-2-ol 30 for min, neat
resin for 4 × 20 min) placed in size 0 gelatine capsules with fresh resin and heat
polymerised overnight at 50 °C. Thin (80 nm) sections were cut on an Ultracut E.
ultramicrotome with a glass knife and collected onto 300 mesh copper grids,
stained with lead citrate and examined in a Philips CM12 (FEI UK Ltd. UK) TEM
at 80 kV. Digital images were captured with a Megaview III digital camera and
AnalySIS (Soft Imaging System GmbH, Germany).
Galleria mellonella infection model. In vivo virulence of seven wild-type MCRPEC
isolates and their HLCRMs (day 0, 3, 7, 11 and 14) were evaluated using G. mel-
lonella infection model. The wax moth G.mellonella in larval stage (Live Foods UK
Ltd., http://www.livefood.co.uk) were stored in dark and used within 3 days from
shipment. Prior to inoculation into larvae, bacterial pellets were washed with sterile
saline and then diluted to an appropriate cell density. Using a 50 µl Hamilton syringe,
10 µl aliquots of serially diluted bacterial suspension (from 103 to 107 c.f.u. per ml)
were injected into the haemocoel of each larvae, through the rear left pro-leg54–57. A
group of 10 larvae were randomly chosen to inject for each level of inoculation in
triplicate. Followed by injection, larvae were incubated at 37 °C, and the survival of
larvae was monitored daily for 3 days. Death was denoted when larvae no longer
responded to touch. Results were analysed by Kaplan–Meier survival curves
(GraphPad Prism statistics software). For all experiments, three control groups were
used: 10 larvae in ﬁrst groups were injected with 10 µl sterile saline, the second group
included larvae that received mock injection to ensure death was not caused by
physical trauma, and the larvae in third group with no injection. In all cases, no dead
larvae were observed in the control groups.
S1 nuclease-based pulsed-ﬁeld gel electrophoresis. To investigate whether mcr-
1 genes were located on plasmids or chromosome, endonuclease S1 pulsed-ﬁeld gel
electrophoresis were assayed as previously described58. Brieﬂy, bacterial DNA was
prepared in agarose blocks and digested with 1 unit of S1 nuclease (Invitrogen).
Electrophoresis was conducted on a CHEF-DR III apparatus (Bio-Rad, Hercules,
CA, USA) under the following conditions: 6 V cm−1 at 14 °C, with an initial pulse
time of 4 s and a ﬁnal pulse time of 45 s for 18 h. In-gel hybridisation was done
with a mcr-1 probe labelled with 32P (Stratgene, Amsterdam, Netherlands) with a
random primer method according to manufacturers’ instruction.
Whole-genome sequencing and bioinformatics analysis. Total gDNA was
extracted from an overnight culture (2 ml) on a QIAcube automated system
(Qiagen). Following extraction, gDNA was quantiﬁed by ﬂuorometric methods
using a Qubit (ThermoFisher Scientiﬁc), with quality ratios of gDNA (A260/280
and 260/230) determined via Nanodrop (ThermoFisher Scientiﬁc). Genomic DNA
libraries are prepared for whole-genome sequencing using the NexteraXT kit
(Illumina), as described by the manufacturer. Paired end sequencing was per-
formed using the Illumina MiSeq platform (MiSeq Reagent V3 Kit; 2 × 300 cycles).
For each E. coli isolate, at least 80× coverage was generated. Raw sequence reads
were trimmed using Trim Galore and the genomes were de novo-assembled into
contigs using SPAdes (3.9.0) with pre-deﬁned kmers set. Raw reads were also
assembled with Geneious (10.0.9; Biomatters Ltd.) de novo assembler, set at
medium sensitivity for analysis of paired Illumina reads. Geneious was used to map
both sets of contigs to reference genes identiﬁed by closest BLAST homology and
was also used to annotate genes from closest homologues in NCBI Genome
database. Resistance genes were identiﬁed using Resﬁnder within CGE59, and
wgMLST proﬁles were generated using the CGE platform coupled with the
PubMLST.org database60. Plasmids were identiﬁed within the genome assembly
and typed using Plasmidﬁnder61.
Analysis of lipid A modiﬁcations. A total of 200 ml overnight culture were
harvested by centrifugation at 10,000×g for 10 min. Lipid A was extracted as
previously described62. In brief, the pellets were washed twice and resuspended in
1× PBS, followed by adding single-phase Bligh-dyer solvent (chloroform: methanol:
water; 1:2:0.8, v/v/v). The mixtures were incubated for 20 min at room temperature
and centrifuged at 2000×g for 20 min. The LPS pellets washed with the single-phase
Bligh-Dyer solvent and resuspended in hydrolysis buffer by boiling the samples in
50 mM sodium acetate (pH 4.5). The samples were sonicated twice (20 s per burst)
and incubated the samples in a boiling water bath for 30 min. Then the lipid A was
extracted using a two-phase Blign-Dyer solvent (chloroform:methanol: water;
2:2:1.8, v/v/v). Once extracted, 10 µl of the puriﬁed Lipid A dissolved in
chloroform-methonal (2:1, v/v) were analysed using a ESI-QTOF mass spec-
trometery (Waters Synapt HR-MS) in the negative-ion mode. The spectral data
were used to analyse the structures of bacterial lipid A from MCRPEC (E. coli
W3110 with plasmid pUC19-mcr-1) and non-MCRPEC (E. coli W3110 with empty
vector pUC19)9.
Data availability. Genomic sequences of bacterial strains have been deposited in
the NCBI GenBank with accession codes MG489944, MG557851, MG557852,
MG557853, and MG557854; there are two sequencing data still outstanding. Other
relevant data supporting the ﬁndings of the study are available in this article and its
Supplementary Information ﬁles, or from the corresponding authors upon request.
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